Organization
Hospital U i P La Fe
4 abstracts
Abstract
Recommended phase 2 dose (RP2D) for abemaciclib in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with relapsed/refractory solid tumors (JPCS Part A).Org: Hospital Infantil Universitario Niño Jesús, Vall d'Hebron Barcelona Hospital Campus, National Cancer Center Hospital East, Kashiwa, Japan, Fondazione Policlinico Universitario A. Gemelli IRCCS, Phoenix Children's Hospital,
Abstract
Prognostic factors of early mortality in children and adolescents enrolled in oncology trials with a dose-finding part in the era of targeted and immune therapies: An Innovative Therapies for Children with Cancer (ITCC) study.Org: The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Prinses Máxima Center for Pediatric Oncology, Institute Gustave Roussy, SIREDO Oncology Center, Institut Curie, Saint Cloud, France,
Abstract
A randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in participants with relapsed or refractory Ewing sarcoma.Org: Eli Lilly and Company, Pediatric Oncology-Hematology Department, National Cancer Center Hospital East, Kashiwa, Japan, Hospital U i P La Fe, Peter MacCallum Cancer Centre, Melbourne, Australia,
Abstract
Safety and PK (pharmacokinetic) profile of niraparib (nir) + dostarlimab (dost) in pediatric patients (pts) with recurrent or refractory (RR) solid tumors: SCOOP study.Org: Institut Curie, Saint Cloud, France, University of Paris-Saclay, Hôpital Pour Enfants De La Timone, Hospital Universitario 12 de Octubre, Hospital U i P La Fe,